Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Earle Bain

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Schizophrenia Bulletin|February 12, 2014
A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophreniaGeorge M Haig, Earle Bain, Weining Robieson, et al.
Journal of Clinical Pharmacology|April 17, 2019
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFRRajendar K Mittapalli, Sven Stodtmann, Anna Friedel, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2004
Reduced serotonin type 1A receptor binding in panic disorderAlexander Neumeister, Earle Bain, Allison C Nugent, et al.
The American Journal of Psychiatry|January 29, 2005
No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorderOmer Bonne, Earle Bain, Alexander Neumeister, et al.
Ophthalmic Research|May 31, 2023
A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab MafodotinColin J Vize, Stella K Kim, Tim Matthews, et al.
Neuro-Oncology|May 25, 2019
Defining EGFR amplification status for clinical trial inclusionPim J French, Marica Eoli, Juan Manuel Sepulveda, et al.
Journal of Neuro-Oncology|July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaAndrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Schizophrenia Bulletin|February 12, 2014
A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophreniaGeorge M Haig, Earle Bain, Weining Robieson, et al.
Journal of Clinical Pharmacology|April 17, 2019
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFRRajendar K Mittapalli, Sven Stodtmann, Anna Friedel, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2004
Reduced serotonin type 1A receptor binding in panic disorderAlexander Neumeister, Earle Bain, Allison C Nugent, et al.
The American Journal of Psychiatry|January 29, 2005
No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorderOmer Bonne, Earle Bain, Alexander Neumeister, et al.
Ophthalmic Research|May 31, 2023
A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab MafodotinColin J Vize, Stella K Kim, Tim Matthews, et al.
Neuro-Oncology|May 25, 2019
Defining EGFR amplification status for clinical trial inclusionPim J French, Marica Eoli, Juan Manuel Sepulveda, et al.
Journal of Neuro-Oncology|July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaAndrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Pageof 1